Literature DB >> 28922260

Increased Risk of Inflammatory Bowel Disease in a Population-based Cohort Study of Patients With Hirschsprung Disease.

Anna Löf Granström1, Leila Amin1, Henrik Arnell2, Tomas Wester1.   

Abstract

OBJECTIVES: Hirschsprung disease (HSCR) has previously been associated with inflammatory bowel disease (IBD). There are no data to show how common this association is. The aim of the present study was to assess the risk of IBD in individuals with HSCR in a population-based cohort.
METHODS: This was a nationwide, population-based cohort study. The study exposure was HSCR and the study outcome was IBD. The cohort included all individuals with HSCR registered in the Swedish National Patient Register between 1964 and 2013 and 10 age- and sex-matched controls per patient, randomly selected from the Swedish Population Register. Individuals with IBD were identified in the Swedish National Patient Register. Data were validated by checking for relevant surgical procedures, and, or prescription of drugs for IBD registered in the Swedish Drug Registry.
RESULTS: The cohort comprised 739 individuals with HSCR (565 boys) and 7390 controls (5650 boys). The median age at diagnosis of IBD was not different between the groups; 19 years (5-34) versus 21 years (7-37), P = 0.21. Twenty of the 739 individuals with HSCR and 41 of the 7390 controls had IBD, odds ratio 4.99, and 95% confidence interval 2.85 to 8.45. In the exposed group, 15 individuals had Crohn disease and 5 ulcerative colitis at their latest admission compared to 18 individuals with Crohn disease and 23 with ulcerative colitis in the unexposed group, P = 0.030.
CONCLUSION: There is an increased risk of IBD in patients with HSCR, which should be considered in clinical practice.

Entities:  

Mesh:

Year:  2018        PMID: 28922260     DOI: 10.1097/MPG.0000000000001732

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Neurotrophic factor GDNF regulates intestinal barrier function in inflammatory bowel disease.

Authors:  Michael Meir; Natalie Burkard; Hanna Ungewiß; Markus Diefenbacher; Sven Flemming; Felix Kannapin; Christoph-Thomas Germer; Matthias Schweinlin; Marco Metzger; Jens Waschke; Nicolas Schlegel
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

Review 2.  ERNICA guidelines for the management of rectosigmoid Hirschsprung's disease.

Authors:  Kristiina Kyrklund; Cornelius E J Sloots; Ivo de Blaauw; Kristin Bjørnland; Udo Rolle; Duccio Cavalieri; Paola Francalanci; Fabio Fusaro; Annette Lemli; Nicole Schwarzer; Francesco Fascetti-Leon; Nikhil Thapar; Lars Søndergaard Johansen; Dominique Berrebi; Jean-Pierre Hugot; Célia Crétolle; Alice S Brooks; Robert M Hofstra; Tomas Wester; Mikko P Pakarinen
Journal:  Orphanet J Rare Dis       Date:  2020-06-25       Impact factor: 4.123

3.  Identification and validation of the common pathogenesis and hub biomarkers in Hirschsprung disease complicated with Crohn's disease.

Authors:  Jing Wang; Zejian Li; Jun Xiao; Luyao Wu; Ke Chen; Tianqi Zhu; Chenzhao Feng; Didi Zhuansun; Xinyao Meng; Jiexiong Feng
Journal:  Front Immunol       Date:  2022-09-28       Impact factor: 8.786

4.  Disparities in the gut metabolome of post-operative Hirschsprung's disease patients.

Authors:  Vera Plekhova; Ellen De Paepe; Katrien Van Renterghem; Myriam Van Winckel; Lieselot Y Hemeryck; Lynn Vanhaecke
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

5.  Very Early Onset of Inflammatory Bowel Disease in a Patient With Long-Segment Hirschsprung's Disease.

Authors:  Sharon Wolfson; Kristin Whitfield Van Buren
Journal:  ACG Case Rep J       Date:  2020-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.